Precision Oncology's Messerschmidt in Managed Healthcare Executive Q&A: Innovative Strategies Help Fight Multiple Myeloma


In Managed Healthcare Executive, Precision Oncology Chief Medical Officer Dr. Gerry Messerschmidt discusses the many recent advances in treating multiple myeloma.Innovative strategies and combinations of approved and experimental therapies have a high likelihood of gaining approval and becoming standard use. “This means more therapy, more often—and thus, potential financial ramifications for payers of myeloma treatment,” Messerschmidt said.


To read the complete Q&A, please click here.


Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.